XLV (Health Care Select Sector SPDR Fund) is a large, liquid U.S. healthcare sector ETF designed to track the Health Care Select Sector Index, which represents S&P 500 health care constituents. In practice, that means the fund’s day-to-day movement is dominated by mega-cap managed care, pharmaceuticals, and medical devices rather than early-stage biotech—so headline moves in names like UnitedHealth, Johnson & Johnson, Eli Lilly, AbbVie, Merck, Abbott, and similar bellwethers typically explain most of the ETF’s variance.

Because today is Sunday (April 5, 2026), U.S.-listed ETFs like XLV generally are not trading during regular exchange hours, so many broker screens show “0.00%” as a placeholder versus the last official close. Any meaningful repricing for XLV usually shows up when the underlying U.S. equity market reopens, especially if weekend news changes expectations for the sector’s largest constituents.

The biggest current healthcare headline risk/reward driver is the new wave of obesity/diabetes therapies—specifically Eli Lilly’s FDA approval of Foundayo (orforglipron), an oral GLP-1 for obesity/overweight adults, with shipping expected to begin Monday, April 6, 2026. This matters for XLV because it can move large index-heavy pharma exposure (via Lilly and peers/competitors) and it also has second-order impacts across the healthcare ecosystem (payer utilization trends, pricing/coverage negotiations, downstream medical-cost dynamics). (apnews.com)

Beyond single-stock headlines, XLV is being shaped by (a) defensive sector rotation when growth leadership gets crowded and investors want earnings durability, and (b) healthcare policy/regulatory expectations—especially Medicare Advantage and Part D rulemaking that can affect managed-care profitability and sentiment. CMS finalized a Medicare Advantage/Part D rule on April 2, 2026, which keeps policy uncertainty in focus for the managed-care slice of XLV. (cms.gov)